carmustine / Generic mfg. - LARVOL DELTA

IELSG32: Trial for Patients With Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma (clinicaltrials.gov) - P2 | N=227 | Completed | Sponsor: International Extranodal Lymphoma Study Group (IELSG) | N=126 ➔ 227

Enrollment change • CNS Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Primary Central Nervous System Lymphoma • Transplantation

MARIBAVIR TREATMENT IN AGGRESSIVE EBV-ASSOCIATED POSTTRANSPLANT LYMPHOPROLIFERATIVE DISORDER (EBV+ PTLD) (EBMT 2026) - "She received the VCAP-AMP-VECP regimen plus intrathecal chemotherapy for 4 cycles with Ropeginterferon alfa-2b for skin involvement...GVHD prophylaxis with cyclosporine and mycophenolate was tapered within three months due to Pneumocystis jirovecii pneumonitis...Treatment included carmustine, brentuximab vedotin, venetoclax, azacitidine, and two donor lymphocyte infusions (5M/kg CD3+ T cells each). She developed severe liver and GI GVHD (bilirubin 15.4 mg/dL), requiring steroids, tacrolimus, mycophenolate, abatacept, ATG (1mg/kg), and ruxolitinib (40mg daily)... Approximately half of EBV+ PTLD cases show relapse or resistance to initial RIS or Rituximab-based treatments. While no clinical trials have proven maribavir efficacy in EBV+ PTLD, this case demonstrates promising results in a complex post-transplant setting with multiple complications, highlighting the need for further research in this unmet medical need."

Post-transplantation • Adult T-Cell Leukemia-Lymphoma • Epstein-Barr Virus Infections • Genetic Disorders • Graft versus Host Disease • Hematological Malignancies • Immunology • Infectious Disease • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Obesity • Pneumonia • Respiratory Diseases • Septic Shock • Transplantation

MMR SEROLOGIC STATUS IN MULTIPLE SCLEROSIS AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION (EBMT 2026) - "Background: Multiple sclerosis (MS) patients undergoing autologous stem cell transplantation (ASCT) after carmustine, cytarabine, etoposide, melphalan (BEAM) or cyclophosphamide (Cy) chemotherapy plus rabbit anti-thymocyte globulin (rATG) are considered as naïve to vaccines and offered revaccination; live vaccines as measles/mumps/rubella (MMR) are not recommended before 24 months from ASCT with concern about vaccine-induced infectious disease...The two patients who lost either MMR (ID23) or rubella immunity (ID35) had both low titles at baseline; prior to ASCT, they had received interferon and 3 lines of therapy (interferon, fingolimod, ocrelizumab), respectively... In our real-life population of ASCT-treated MS, the vast majority of patients retained MMR immunity with a slight decline of vaccine titres over time confirming that MMR revaccination could be safely postponed after 24 months from ASCT and probably offered only in selected patients at high risk (i.e...."

CNS Disorders • Infectious Disease • Measles • Multiple Sclerosis • Mumps • Rubella • Transplantation

AUTOLOGOUS TRANSPLANT IN T-CELL LYMPHOMAS (EBMT 2026) - "Consolidation with autologous transplant in patients with T-cell lymphoma offers survival rates above 70%. Carmustine based regimens like BEAM or, CBV, and bendamustine-based regimens were all equally effective. Achieving complete response prior to transplant and requiring fewer lines of therapy to achieve it are the most important variables for clinical decision-making."

Bone Marrow Transplantation • Hematological Malignancies • Human Immunodeficiency Virus • Infectious Disease • Lymphoma • Non-Hodgkin’s Lymphoma • Peripheral T-cell Lymphoma • T Cell Non-Hodgkin Lymphoma • Transplantation • ALK

CLINICAL STUDY OF AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION PLUS UMBILICAL CORD BLOOD STEM CELL TRANSPLANTATION FOR THE RELAPSED AND REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (EBMT 2026) - "The BEAM conditioning included carmustine (300 mg/m²), etoposide (200 mg/m²), cytarabine (300 mg/m²), and melphalan (140 mg/m²). The findings of this study suggest that auto-HSCT combined with unrelated hUCBSCs infusion markedly enhances patients' quality of life. Further validation of the regimen's feasibility will rely on an expanded patient cohort and prolonged follow-up for in-depth assessment."

Clinical • B Cell Lymphoma • Bone Marrow Transplantation • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Transplantation • CD34

MODIFIED BEAC AS BRIDGING/LYMPHODEPLETION THERAPY FOLLOWED BY CAR-T AND STEM CELL SUPPORT IN RELAPSED OR REFRACTORY DLBCL PATIENTS: SAFETY AND EFFICACY OUTCOMES IN 17 PATIENTS (EBMT 2026) - "The lymphodepletion regime of these patients was modified BEAC regime, include carmustine (125mg/m2 on Day −8 to Day −7), etoposide (125 mg/m2, Day −6 to Day −3), cytarabine (250 mg/m2, Day −6 to Day −3), and cyclophosphamide (45 mg/kg, Day −7 to Day −6). The combination of CAR-T cell therapy with hematopoietic stem cell infusion following a modified BEAC regimen demonstrated promising efficacy and manageable toxicity in patients with r/r DLBCL. The modified BEAC regimen enabled timely hematopoietic recovery."

CAR T-Cell Therapy • Clinical • Diffuse Large B Cell Lymphoma • Infectious Disease • Leukopenia • Neutropenia • Thrombocytopenia

OUTCOME OF AGGRESSIVE B-CELL LYMPHOMA ADMINISTERED WITH CAR T-CELL ALONE OR IN COMBINATION WITH ASCT: A PROPENSITY SCORE MATCHING COHORT STUDY (EBMT 2026) - P=N/A | "The two groups were well balanced across all baseline characteristics after PSM, and were appropriate for further comparative analysis of outcomes.Patients who had previously received CAR-T therapy or ASCT were excluded.The conditioning regimen for the ASCT+CAR-T group was standard BEAM (bis-carmustine, etoposide, cytarabine, and melphalan) , while CAR-T cells were transfused within two days after transfusion of CD34+ HSCs in ASCT+CAR-T. Compared to CAR-T therapy alone, the combination of ASCT and CAR-T therapy showed a trend of improved survival outcomes in patients with relapsed/refractory (R/R) B-cell lymphoma. However, a larger study is required to confirm these findings."

CAR T-Cell Therapy • Combination therapy • B Cell Lymphoma • Bone Marrow Transplantation • Hematological Malignancies • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • CD34

ANTI-THYMOCYTE GLOBULIN IN GVHD PROPHYLAXIS FOR AML PATIENTS EXPOSED TO PD-1 BLOCKADE UNDERGOING ALLOGENEIC TRANSPLANTATION (EBMT 2026) - P2 | "All recipients underwent myeloablative conditioning with either modified BuCy-based regimen (busulfan, carmustine, cytarabine and cyclophosphamide) or modified FB-based regimen (Cy in the BuCy regimen was replaced with fludarabine). For GVHD prophylaxis, cyclosporine A (CsA), mycophenolate mofetil (MMF), short-course methotrexate (MTX), with or without ATG were administered... Our study demonstrated that, in addition to PTCy-based regimens, GVHD prophylaxis regimens containing ATG can also counteract the increased GVHD incidence associated with prior exposure to PD-1 inhibitors. Notably, the addition of low-dose PTCy to ATG did not further reduce the risk of both acute and chronic GVHD post transplantation. Therefore, the use of ATG alone or combined with low-dose PTCy appears feasible for GVHD prophylaxis in PD-1 inhibitor-exposed AML patients undergoing alloHCT."

Clinical • Acute Graft versus Host Disease • Acute Myelogenous Leukemia • Chronic Graft versus Host Disease • Graft versus Host Disease • Hematological Malignancies • Immunology • Leukemia • Transplantation

COMPARISON OF CARMUSTINE-, LOMUSTINE-, AND NITROSOUREA-FREE CONDITIONING REGIMENS FOR AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION IN LYMPHOMA: RESULTS FROM THE BRAZILIAN REGISTRY (EBMT 2026) - "In this large national cohort, outcomes after auto-HCT for lymphoma were comparable across carmustine-, lomustine-, and nitrosourea-free conditioning regimens, supporting their interchangeability when specific agents are unavailable."

B Cell Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Large B Cell Lymphoma • Lymphoma • Mantle Cell Lymphoma • Non-Hodgkin’s Lymphoma • Transplantation

COULD PROPHYLACTIC NASOGASTRIC TUBE FEEDING REDUCE WEIGHT LOSS FOR PATIENTS UNDERGOING HIGH-TOXICITY CONDITIONING REGIMENS DURING AUTOLOGOUS STEM CELL TRANSPLANT? (EBMT 2026) - " Three hundred and eighty four patient were included, 60% male, median age 58 years, 69% had multiple myeloma, 21% Non-Hodgkin lymphoma, 51% were conditioned with melphalan 200, 20% with L(B)EAM (lomustine or carmustine with cytarabine, etoposide and melphalan), 19% with melphalan 140, 10% with TT-BNCU (thiotepa and carmustine). Haematological cancer patients undergoing auto-SCT with TT-BNCU or L(B)EAM conditioning regimens are at significantly higher risk of early weight loss and longer hospital stay compared to those receiving melphalan 200 and 140. These results highlight a potential role for prophylactic nasogastric tube feeding in patients receiving high-toxicity regimens to minimise unintentional weight loss and support nutritional recovery throughout auto-SCT to reduce length of stay. Further prospective research is warranted to evaluate the feasibility, safety and long-term impact of prophylactic nasogastric tube feeding in patients receiving high-toxicity..."

Clinical • Hematological Malignancies • Lymphoma • Multiple Myeloma • Non-Hodgkin’s Lymphoma • Transplantation

COULD PROPHYLACTIC NASOGASTRIC TUBE FEEDING REDUCE WEIGHT LOSS FOR PATIENTS UNDERGOING HIGH-TOXICITY CONDITIONING REGIMENS DURING AUTOLOGOUS STEM CELL TRANSPLANT? (EBMT 2026) - " Three hundred and eighty four patient were included, 60% male, median age 58 years, 69% had multiple myeloma, 21% Non-Hodgkin lymphoma, 51% were conditioned with melphalan 200, 20% with L(B)EAM (lomustine or carmustine with cytarabine, etoposide and melphalan), 19% with melphalan 140, 10% with TT-BNCU (thiotepa and carmustine). Haematological cancer patients undergoing auto-SCT with TT-BNCU or L(B)EAM conditioning regimens are at significantly higher risk of early weight loss and longer hospital stay compared to those receiving melphalan 200 and 140. These results highlight a potential role for prophylactic nasogastric tube feeding in patients receiving high-toxicity regimens to minimise unintentional weight loss and support nutritional recovery throughout auto-SCT to reduce length of stay. Further prospective research is warranted to evaluate the feasibility, safety and long-term impact of prophylactic nasogastric tube feeding in patients receiving high-toxicity..."

Clinical • Hematological Malignancies • Lymphoma • Multiple Myeloma • Non-Hodgkin’s Lymphoma • Transplantation

MMR SEROLOGIC STATUS IN MULTIPLE SCLEROSIS AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION (EBMT 2026) - "Background: Multiple sclerosis (MS) patients undergoing autologous stem cell transplantation (ASCT) after carmustine, cytarabine, etoposide, melphalan (BEAM) or cyclophosphamide (Cy) chemotherapy plus rabbit anti-thymocyte globulin (rATG) are considered as naïve to vaccines and offered revaccination; live vaccines as measles/mumps/rubella (MMR) are not recommended before 24 months from ASCT with concern about vaccine-induced infectious disease...The two patients who lost either MMR (ID23) or rubella immunity (ID35) had both low titles at baseline; prior to ASCT, they had received interferon and 3 lines of therapy (interferon, fingolimod, ocrelizumab), respectively... In our real-life population of ASCT-treated MS, the vast majority of patients retained MMR immunity with a slight decline of vaccine titres over time confirming that MMR revaccination could be safely postponed after 24 months from ASCT and probably offered only in selected patients at high risk (i.e...."

CNS Disorders • Infectious Disease • Measles • Multiple Sclerosis • Mumps • Rubella • Transplantation

CLINICAL STUDY OF AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION PLUS UMBILICAL CORD BLOOD STEM CELL TRANSPLANTATION FOR THE RELAPSED AND REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (EBMT 2026) - "The BEAM conditioning included carmustine (300 mg/m²), etoposide (200 mg/m²), cytarabine (300 mg/m²), and melphalan (140 mg/m²). The findings of this study suggest that auto-HSCT combined with unrelated hUCBSCs infusion markedly enhances patients' quality of life. Further validation of the regimen's feasibility will rely on an expanded patient cohort and prolonged follow-up for in-depth assessment."

Clinical • B Cell Lymphoma • Bone Marrow Transplantation • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Transplantation • CD34

MODIFIED BEAC AS BRIDGING/LYMPHODEPLETION THERAPY FOLLOWED BY CAR-T AND STEM CELL SUPPORT IN RELAPSED OR REFRACTORY DLBCL PATIENTS: SAFETY AND EFFICACY OUTCOMES IN 17 PATIENTS (EBMT 2026) - "The lymphodepletion regime of these patients was modified BEAC regime, include carmustine (125mg/m2 on Day −8 to Day −7), etoposide (125 mg/m2, Day −6 to Day −3), cytarabine (250 mg/m2, Day −6 to Day −3), and cyclophosphamide (45 mg/kg, Day −7 to Day −6). The combination of CAR-T cell therapy with hematopoietic stem cell infusion following a modified BEAC regimen demonstrated promising efficacy and manageable toxicity in patients with r/r DLBCL. The modified BEAC regimen enabled timely hematopoietic recovery."

CAR T-Cell Therapy • Clinical • Diffuse Large B Cell Lymphoma • Infectious Disease • Leukopenia • Neutropenia • Thrombocytopenia

OUTCOME OF AGGRESSIVE B-CELL LYMPHOMA ADMINISTERED WITH CAR T-CELL ALONE OR IN COMBINATION WITH ASCT: A PROPENSITY SCORE MATCHING COHORT STUDY (EBMT 2026) - P=N/A | "The two groups were well balanced across all baseline characteristics after PSM, and were appropriate for further comparative analysis of outcomes.Patients who had previously received CAR-T therapy or ASCT were excluded.The conditioning regimen for the ASCT+CAR-T group was standard BEAM (bis-carmustine, etoposide, cytarabine, and melphalan) , while CAR-T cells were transfused within two days after transfusion of CD34+ HSCs in ASCT+CAR-T. Compared to CAR-T therapy alone, the combination of ASCT and CAR-T therapy showed a trend of improved survival outcomes in patients with relapsed/refractory (R/R) B-cell lymphoma. However, a larger study is required to confirm these findings."

CAR T-Cell Therapy • Combination therapy • B Cell Lymphoma • Bone Marrow Transplantation • Hematological Malignancies • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • CD34

AUTOLOGOUS TRANSPLANT IN T-CELL LYMPHOMAS (EBMT 2026) - "Consolidation with autologous transplant in patients with T-cell lymphoma offers survival rates above 70%. Carmustine based regimens like BEAM or, CBV, and bendamustine-based regimens were all equally effective. Achieving complete response prior to transplant and requiring fewer lines of therapy to achieve it are the most important variables for clinical decision-making."

Bone Marrow Transplantation • Hematological Malignancies • Human Immunodeficiency Virus • Infectious Disease • Lymphoma • Non-Hodgkin’s Lymphoma • Peripheral T-cell Lymphoma • T Cell Non-Hodgkin Lymphoma • Transplantation • ALK

ANTI-THYMOCYTE GLOBULIN IN GVHD PROPHYLAXIS FOR AML PATIENTS EXPOSED TO PD-1 BLOCKADE UNDERGOING ALLOGENEIC TRANSPLANTATION (EBMT 2026) - P2 | "All recipients underwent myeloablative conditioning with either modified BuCy-based regimen (busulfan, carmustine, cytarabine and cyclophosphamide) or modified FB-based regimen (Cy in the BuCy regimen was replaced with fludarabine). For GVHD prophylaxis, cyclosporine A (CsA), mycophenolate mofetil (MMF), short-course methotrexate (MTX), with or without ATG were administered... Our study demonstrated that, in addition to PTCy-based regimens, GVHD prophylaxis regimens containing ATG can also counteract the increased GVHD incidence associated with prior exposure to PD-1 inhibitors. Notably, the addition of low-dose PTCy to ATG did not further reduce the risk of both acute and chronic GVHD post transplantation. Therefore, the use of ATG alone or combined with low-dose PTCy appears feasible for GVHD prophylaxis in PD-1 inhibitor-exposed AML patients undergoing alloHCT."

Clinical • Acute Graft versus Host Disease • Acute Myelogenous Leukemia • Chronic Graft versus Host Disease • Graft versus Host Disease • Hematological Malignancies • Immunology • Leukemia • Transplantation

COMPARISON OF CARMUSTINE-, LOMUSTINE-, AND NITROSOUREA-FREE CONDITIONING REGIMENS FOR AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION IN LYMPHOMA: RESULTS FROM THE BRAZILIAN REGISTRY (EBMT 2026) - "In this large national cohort, outcomes after auto-HCT for lymphoma were comparable across carmustine-, lomustine-, and nitrosourea-free conditioning regimens, supporting their interchangeability when specific agents are unavailable."

B Cell Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Large B Cell Lymphoma • Lymphoma • Mantle Cell Lymphoma • Non-Hodgkin’s Lymphoma • Transplantation

COULD PROPHYLACTIC NASOGASTRIC TUBE FEEDING REDUCE WEIGHT LOSS FOR PATIENTS UNDERGOING HIGH-TOXICITY CONDITIONING REGIMENS DURING AUTOLOGOUS STEM CELL TRANSPLANT? (EBMT 2026) - " Three hundred and eighty four patient were included, 60% male, median age 58 years, 69% had multiple myeloma, 21% Non-Hodgkin lymphoma, 51% were conditioned with melphalan 200, 20% with L(B)EAM (lomustine or carmustine with cytarabine, etoposide and melphalan), 19% with melphalan 140, 10% with TT-BNCU (thiotepa and carmustine). Haematological cancer patients undergoing auto-SCT with TT-BNCU or L(B)EAM conditioning regimens are at significantly higher risk of early weight loss and longer hospital stay compared to those receiving melphalan 200 and 140. These results highlight a potential role for prophylactic nasogastric tube feeding in patients receiving high-toxicity regimens to minimise unintentional weight loss and support nutritional recovery throughout auto-SCT to reduce length of stay. Further prospective research is warranted to evaluate the feasibility, safety and long-term impact of prophylactic nasogastric tube feeding in patients receiving high-toxicity..."

Clinical • Hematological Malignancies • Lymphoma • Multiple Myeloma • Non-Hodgkin’s Lymphoma • Transplantation

International Survey for Antiemetics in Hematopoietic Stem Cell Transplantation in the APBMT Centers. (PubMed, Blood Cell Ther) - "Although recent guidelines recommend a triple combination of a 5-hydroxytryptamine-3 (5-HT3) receptor antagonist, dexamethasone, and an neurokinin 1 (NK1) receptor antagonist, antiemetic practices vary widely across countries and regions...The most commonly used conditioning regimens for allogeneic HSCT were busulfan and cyclophosphamide (Bu-CY) (72%) and fludarabine and busulfan (Flu-Bu) (62%), whereas high-dose melphalan (83%) and carmustine (BCNU), etoposide, cytarabine arabinoside, and melphalan (BEAM) (69%) were predominant for autologous HSCT...Given the complexity of HSCT and the varying side effect profiles of antiemetic agents, a multidisciplinary approach to treatment planning, including that of pharmacists and dietitians, could optimize supportive care. Future prospective studies are warranted to evaluate the safety, efficacy, and feasibility of olanzapine- and steroid-sparing antiemetic strategies to improve patient outcomes."

Journal • Bone Marrow Transplantation • Chemotherapy-Induced Nausea and Vomiting • Transplantation

Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (clinicaltrials.gov) - P3 | N=94 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Dec 2025 ➔ Dec 2026

Trial completion date • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Transplantation • BCL2

A Study of Melphalan in People With Lymphoma Getting an Autologous Hematopoietic Cell Transplant (clinicaltrials.gov) - P1 | N=39 | Active, not recruiting | Sponsor: Memorial Sloan Kettering Cancer Center | Recruiting ➔ Active, not recruiting | Trial completion date: Sep 2026 ➔ Sep 2027 | Trial primary completion date: Sep 2026 ➔ Sep 2027

Enrollment closed • Trial completion date • Trial primary completion date • B Cell Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • T Cell Non-Hodgkin Lymphoma • Transplantation • CD34

A network-driven computational framework for identifying FDA-approved drug repurposing across heterogeneous brain cancers. (PubMed, Front Mol Biosci) - "As a result, three repurposed drugs were identified as priorities: (i) mefloquine (reference drug: vorasidenib citrate), (ii) clofibric acid (reference drug: carmustine), and armillarisin A (reference drug: lomustine). These results also suggest repurposing candidates for synergistic combinations across different brain tumors. The two applications developed in this work are freely accessible and in the public domain at https://assay.smallmoles.com/escorwin."

FDA event • Heterogeneity • Journal • Brain Cancer • Oncology • Solid Tumor • BRAF • CDK1 • EGFR • KDR • PDGFRA • TERT • TP53

Clinical Outcomes of Autologous Hematopoietic Stem Cell Transplantation in Filipino Patients With Multiple Sclerosis: A Single-Center Retrospective Case Series. (PubMed, Cureus) - "aHSCT was well tolerated and associated with short-term clinical stability in Filipino patients with active RRMS and SPMS. During follow-up, all patients remained relapse-free without evidence of confirmed disability progression. These findings support the role of aHSCT as a viable therapeutic option in settings with limited access to high-efficacy DMTs. Larger studies with longer follow-up are needed to evaluate the durability of remission."

Clinical data • Journal • Retrospective data • Bone Marrow Transplantation • CNS Disorders • Febrile Neutropenia • Hematological Disorders • Infectious Disease • Multiple Sclerosis • Neutropenia • Transplantation

SCC215/P002900: Optimizing MATRix, a combination of Methotrexate, Ara-C, Thiotepa and Rituximab given as an induction therapy, de-escalated in duration and total drug dose in comparison to the standard induction therapy and both treatments followed by a high dose therapy with autologous stem cell transplantation. The therapy is for patients with newly diagnosed primary lymphoma of the central... (clinicaltrialsregister.eu) - P2/3 | N=286 | Active, not recruiting | Sponsor: Klinikum Der Landeshauptstadt Stuttgart gKAR | Recruiting ➔ Active, not recruiting

Enrollment closed • B Cell Lymphoma • Brain Cancer • CNS Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Primary Central Nervous System Lymphoma • Rare Diseases • Solid Tumor • Transplantation